BiotechTube

RZ358 Sequential Group Cohort 1 + RZ358 Sequential Group Cohort 2 + RZ358 Sequential Group Cohort 3 + RZ358 Sequential Group Cohort 4

Phase 2Completed
0 views this week 0 watching💤 Quiet
Interest: 25/100
25
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Congenital Hyperinsulinism

Conditions

Congenital Hyperinsulinism

Trial Timeline

Feb 24, 2020 → Aug 19, 2022

NCT ID
NCT04538989

About RZ358 Sequential Group Cohort 1 + RZ358 Sequential Group Cohort 2 + RZ358 Sequential Group Cohort 3 + RZ358 Sequential Group Cohort 4

RZ358 Sequential Group Cohort 1 + RZ358 Sequential Group Cohort 2 + RZ358 Sequential Group Cohort 3 + RZ358 Sequential Group Cohort 4 is a phase 2 stage product being developed by Rezolute for Congenital Hyperinsulinism. The current trial status is completed. This product is registered under clinical trial identifier NCT04538989. Target conditions include Congenital Hyperinsulinism.

What happened to similar drugs?

4 of 20 similar drugs in Congenital Hyperinsulinism were approved

Approved (4) Terminated (0) Active (16)
🔄turoctocog alfa + turoctocog alfaNovo NordiskPhase 3
🔄turoctocog alfa pegolNovo NordiskPhase 3
🔄nonacog beta pegolNovo NordiskPhase 3
🔄vatreptacog alfa (activated) + eptacog alfa (activated)Novo NordiskPhase 3
🔄nonacog beta pegolNovo NordiskPhase 3
🔄turoctocog alfa + turoctocog alfaNovo NordiskPhase 3
✅turoctocog alfaNovo NordiskApproved

Hype Score Breakdown

Clinical
12
Activity
8
Company
5
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT04538989Phase 2Completed

Competing Products

20 competing products in Congenital Hyperinsulinism

See all competitors
ProductCompanyStageHype Score
TideglusibAMO PharmaPre-clinical
20
Tideglusib + PlaceboAMO PharmaPhase 2/3
28
TideglusibAMO PharmaPhase 2/3
35
EDIT-101Editas MedicinePhase 1/2
18
Tildacerfont/PlaceboSpruce BiosciencesPhase 2
17
SPR001Spruce BiosciencesPhase 2
25
SPR001Spruce BiosciencesPhase 2
25
Tildacerfont/PlaceboSpruce BiosciencesPhase 2
17
TildacerfontSpruce BiosciencesPhase 2
17
KW-3357Kyowa KirinPhase 1
29
Pasireotide 0.6Mg Solution for Injection + Saline SolutionNovartisPhase 2
27
Sandostatine LPNovartisPhase 2
35
mycophenolate mofetilRochePhase 1
29
turoctocog alfa + turoctocog alfaNovo NordiskPhase 3
40
catridecacog + recombinant factor XIIINovo NordiskPhase 1
29
activated recombinant human factor VIINovo NordiskPhase 2
35
turoctocog alfa pegolNovo NordiskPhase 3
40
recombinant factor XIIINovo NordiskPre-clinical
26
activated recombinant human factor VII, long acting + activated recombinant human factor VII, long actingNovo NordiskPhase 1
29
Advate® + turoctocog alfaNovo NordiskPhase 1
29